Targeting GRK2 by gene therapy for heart failure: benefits above β-blockade

Heart failure (HF) is a common pathological end point for several cardiac diseases. Despite reasonable achievements in pharmacological, electrophysiological and surgical treatments, prognosis for chronic HF remains poor. Modern therapies are generally symptom oriented and do not currently address sp...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Gene therapy 2012-06, Vol.19 (6), p.686-693
Hauptverfasser:	Reinkober, J, Tscheschner, H, Pleger, S T, Most, P, Katus, H A, Koch, W J, Raake, P W J
Format:	Artikel
Sprache:	eng
Schlagworte:	631/154/51/201 631/208/205 631/45/607/275 692/699/75/230 Adrenergic beta-Antagonists - therapeutic use Adrenergic receptors b-Adrenergic-receptor kinase beta -Adrenergic-receptor kinase Biomedical and Life Sciences Biomedicine Care and treatment Cell Biology Combined Modality Therapy Congestive heart failure Coronary artery disease Development Expression vectors G protein-coupled receptors G-Protein-Coupled Receptor Kinase 2 - genetics G-Protein-Coupled Receptor Kinase 2 - physiology Gene Expression Gene Targeting - methods Gene Therapy Genetic aspects Genetic Therapy - methods Health aspects Heart diseases Heart failure Heart Failure - physiopathology Heart Failure - therapy Human Genetics Humans Intracellular Intracellular signalling Kinases Medical innovations Myocytes Nanotechnology Physiological aspects Prognosis Protein kinases Receptor mechanisms review Structure-function relationships
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!